Please wait while the formulary information is being retrieved.
DDAVP (DESMOPRESSIN ACETATE)
- Partial central diabetes insipidus
- Nocturnal enuresis
- Partial central diabetes insipidus
- Hemophilia A
- Von willebrand's disease
- Desmopressin Tablet
- Desmopressin Nasal Spray (non-refrigerated)
- Desmopressin Nasal Solution
- Desmopressin Injection Solution
- Ddavp Tablet
- Ddavp Tab
- Ddavp Nasal Spray With Pump
- Ddavp Nasal Spray Aerosol
- Ddavp Nasal Solution
- Ddavp Nasal Soln
- Ddavp Injection Solution
- Ddavp Injection
- By Indication
0.1 mg tablet
- 1 tablet (0.1 mg) by oral route 2 times per day
0.2 mg tablet
- 1 tablet (0.2 mg) by oral route 2 times per day
desmopressin 0.1 mg tablet
- 1 tablet (0.1 mg) by oral route 2 times per day
desmopressin 0.2 mg tablet
- 1 tablet (0.2 mg) by oral route 2 times per day
desmopressin 10 mcg/spray (0.1 mL) nasal spray (non-refrigerated)
- Spray 0.1 milliliter (10 mcg) by intranasal route 2 times per day in the morning and evening
desmopressin 0.1 mg/mL (refrigerate) nasal solution
- Spray 0.1 milliliter (10 mcg) by intranasal route 2 times per day in the morning and evening
4 mcg/mL injection solution
- Inject 0.25 milliliter (1 mcg) by subcutaneous route 2 times per day
desmopressin 4 mcg/mL injection solution
- Inject 0.25 milliliter (1 mcg) by subcutaneous route 2 times per day
0.1 mg tablet
- 1 tablet (0.1 mg) by oral route 2 times per day
0.2 mg tablet
- 1 tablet (0.2 mg) by oral route 2 times per day
0.1 mg tablet
- 1 tablet (0.1 mg) by oral route 2 times per day
0.2 mg tablet
- 1 tablet (0.2 mg) by oral route 2 times per day
10 mcg/spray (0.1 mL) nasal spray with pump
- Spray 0.1 milliliter (10 mcg) by intranasal route 2 times per day in the morning and evening
10 mcg/spray (0.1 mL) nasal spray with pump
- Spray 0.1 milliliter (10 mcg) by intranasal route 2 times per day in the morning and evening
0.1 mg/mL (refrigerate) nasal solution
- Spray 0.1 milliliter (10 mcg) by intranasal route 2 times per day in the morning and evening
0.1 mg/mL (refrigerate) nasal solution
- Spray 0.1 milliliter (10 mcg) by intranasal route 2 times per day in the morning and evening
4 mcg/mL injection solution
- Inject 0.25 milliliter (1 mcg) by subcutaneous route 2 times per day
4 mcg/mL injection solution
- Inject 0.25 milliliter (1 mcg) by subcutaneous route 2 times per day
Hemophilia A
- Infuse 0.3 mcg/kg by intravenous route once 30 minutes prior to procedure
- Infuse 0.3 mcg/kg slowly over 15-30 minute(s) by intravenous route once
Partial central diabetes insipidus
- 1 tablet (0.1 mg) by oral route 2 times per day
- 1 tablet (0.1 mg) by oral route 3 times per day
- 2 tablets (0.2 mg) by oral route 3 times per day
- 1 tablet (0.2 mg) by oral route 3 times per day
- 2 tablets (0.2 mg) by oral route 2 times per day
- 1 tablet (0.2 mg) by oral route 2 times per day
- 2 tablets (0.4 mg) by oral route 2 times per day
- Inject 0.25 milliliter (1 mcg) by subcutaneous route 2 times per day
- Inject 0.25 milliliter (1 mcg) by intravenous route 2 times per day
- Inject 0.5 milliliter (2 mcg) by intravenous route 2 times per day
- Inject 0.5 milliliter (2 mcg) by subcutaneous route 2 times per day
- Spray 0.05 milliliter (5 mcg) by intranasal route 2 times per day in the morning and evening
- Spray 0.1 milliliter (10 mcg) by intranasal route 2 times per day in the morning and evening
- Spray 0.1 milliliter (10 mcg) by intranasal route once daily
- Spray 0.1 milliliter (10 mcg) by intranasal route 3 times per day
- Spray 0.2 milliliter (20 mcg) by intranasal route 2 times per day in the morning and evening
Von willebrand's disease
- Infuse 0.3 mcg/kg by intravenous route once 30 minutes prior to procedure
- Infuse 0.3 mcg/kg over 15-30 minute(s) by intravenous route
- Infuse 0.3 mcg/kg slowly over 15-30 minute(s) by intravenous route once
- None
Contraindicated
- None
Severe
Moderate
- None
- Chronic kidney disease stage 3A (moderate) GFR 45-59
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Hyponatremia
- Renal disease with moderate to severe impairment
Contraindicated
- Hyponatremia
- Kidney disease with likely reduction in GFR
- Psychogenic polydipsia
- Severe allergic rhinitis
Severe
Moderate
- Allergic rhinitis
- Chronic heart failure
- Coronary artery disease
- Cystic fibrosis
- Hypertension
- Water intoxication
DDAVP (DESMOPRESSIN ACETATE)
- Partial central diabetes insipidus
- Nocturnal enuresis
- Partial central diabetes insipidus
- Hemophilia A
- Von willebrand's disease
- None
- None
More Frequent
Severe
Less Severe
- Hypertension
- Abdominal pain with cramps
- Back pain
- Body fluid retention
- Bronchitis
- Chills
- Dizziness
- Epistaxis
- Headache disorder
- Nasal passage irritation
- Nausea
- Sneezing
- Vulvodynia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Acute respiratory insufficiency
- Anaphylaxis
- Atrial fibrillation
- Chest pain
- Hypertension
- Hyponatremia
- Hypotension
- Seizure disorder
- Water intoxication
Less Severe
- Agitation
- Balanitis
- Cough
- Diarrhea
- Disturbance in thinking
- Drowsy
- Dyspepsia
- Dysuria
- Edema
- Flushing
- Insomnia
- Nasal congestion
- Ocular itching
- Palpitations
- Rhinitis
- Sore throat
- Tachycardia
- Upper respiratory infection
- Vomiting
- Vulvodynia
- Weight gain
Contraindicated
None
Severe Precaution
Desmopressin (Nasal)
Contraindicated for treatment of primary nocturnal enuresis. Risk of water intoxication, hyponatremia and seizure. Monitor fluid intake.
- 1 Day – 18 Years
- Contraindicated for treatment of primary nocturnal enuresis. Risk of water intoxication, hyponatremia and seizure. Monitor fluid intake.
Management or Monitoring Precaution
Desmopressin (select)
Risk of water intoxication, hyponatremia and seizure. Monitor fluid intake.
- 1 Day – 18 Years
- Risk of water intoxication, hyponatremia and seizure. Monitor fluid intake.
Desmopressin Acetate
- Severity Level:
2
- Additional Notes: Limited human data do not suggest a clear association for development toxicity.
Sodium Phosphate,dibasic
- Severity Level:
2
- Additional Notes: Insufficient data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Desmopressin
Limited data suggest negligible amount in breastmilk and poor oral absorption
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | Not known; no or inclusive data | Limited data suggest negligible amount in breastmilk and poor oral absorption |
Contraindicated
None
Precaution Exists
Desmopressin Acetate
General-Avoid for treatment of nocturia or nocturnal polyuria due to risk for hyponatremia. Safer alternatives exist. Use in geriatric patients requires careful fluid intake restriction to prevent possible water intoxication with hyponatremia.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: Y HEDIS: N STOPP: Y
No Known Risk
None
- None
| Hemophilia A | |
| D66 | Hereditary factor VIII deficiency |
| Z14.02 | Symptomatic hemophilia A carrier |
| Nocturnal enuresis | |
| N39.44 | Nocturnal enuresis |
| Partial central diabetes insipidus | |
| E23.2 | Diabetes insipidus |
| Von willebrand's disease | |
| D68.0 | Von willebrand's disease |
| 0-9 | A-Z |
|---|---|
| D66 | Hereditary factor VIII deficiency |
| D68.0 | Von willebrand's disease |
| E23.2 | Diabetes insipidus |
| N39.44 | Nocturnal enuresis |
| Z14.02 | Symptomatic hemophilia A carrier |
Formulary Reference Tool